These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7513844)

  • 21. [Effects of recombinant human granulocyte colony-stimulating factor on superoxide production by neutrophil in cancer patients receiving chemotherapy].
    Yoshida M; Oshi M; Aso Y; Yanagisawa R; Kishi H; Ishida Y
    Nihon Hinyokika Gakkai Zasshi; 1993 Jul; 84(7):1262-8. PubMed ID: 7689123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant granulocyte colony-stimulating factor induces production of human neutrophil peptides in lung cancer patients with neutropenia.
    Ashitani J; Nakazato M; Mukae H; Taniguchi H; Date Y; Matsukura S
    Regul Pept; 2000 Nov; 95(1-3):87-92. PubMed ID: 11062337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
    Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
    Mehdi SA; Perry MC; Herndon JE; Crawford J; Young R; Graziano SL
    J Interferon Cytokine Res; 1998 Aug; 18(8):623-7. PubMed ID: 9726444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical study of recombinant human granulocyte colony stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy in cancer patients].
    Shi YK; Zhou JC; Feng FY
    Zhonghua Zhong Liu Za Zhi; 1994 May; 16(3):207-10. PubMed ID: 7525173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN8601) in patients with advanced malignancy.
    Eguchi K; Sasaki S; Tamura T; Sasaki Y; Shinkai T; Yamada K; Soejima Y; Fukuda M; Fujihara Y; Kunitou H
    Cancer Res; 1989 Sep; 49(18):5221-4. PubMed ID: 2475245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
    Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
    J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
    J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
    Holdsworth MT; Roon R; Ferguson J; Martinez L; Stidley CA; Neidhart JA
    Biotechnol Ther; 1993; 4(3-4):183-95. PubMed ID: 8292969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical Investigation of the Effects of Filgrastim BS1 on Neutropenia Following Oral Cancer Chemotherapy (TPF Therapy)].
    Uchiyama K; Yamada M; Tamate S; Iwasaki K; Mitomo K; Nakayama S
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1073-6. PubMed ID: 26469162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions.
    Hollingshead LM; Goa KL
    Drugs; 1991 Aug; 42(2):300-30. PubMed ID: 1717226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer.
    Soda H; Oka M; Fukuda M; Kinoshita A; Sakamoto A; Araki J; Fujino S; Itoh N; Watanabe K; Kanda T; Nakano M; Hara K
    Cancer Chemother Pharmacol; 1996; 38(1):9-12. PubMed ID: 8603458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
    J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
    Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA; Bermejo B; Gallardo E; Vidal R; Vera R; Eres N; Carulla J; Baselga J
    J Clin Oncol; 1996 May; 14(5):1573-80. PubMed ID: 8622074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
    J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.